Alpine Immune Sciences (ALPN) Upgraded to Buy by Zacks Investment Research

Alpine Immune Sciences (NASDAQ:ALPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The brokerage presently has a $13.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 15.97% from the stock’s previous close.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

Separately, ValuEngine downgraded Alpine Immune Sciences from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. Alpine Immune Sciences currently has an average rating of “Hold” and an average target price of $10.83.

Shares of Alpine Immune Sciences (ALPN) traded down $0.10 during mid-day trading on Thursday, hitting $11.21. The stock had a trading volume of 36,300 shares, compared to its average volume of 22,550. Alpine Immune Sciences has a 12-month low of $7.20 and a 12-month high of $14.52. The company has a quick ratio of 32.38, a current ratio of 32.38 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $155.61 and a price-to-earnings ratio of -1.30.

An institutional investor recently bought a new position in Alpine Immune Sciences stock. Sowell Financial Services LLC acquired a new stake in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) during the third quarter, according to its most recent filing with the SEC. The fund acquired 15,714 shares of the biotechnology company’s stock, valued at approximately $162,000. Sowell Financial Services LLC owned 0.40% of Alpine Immune Sciences as of its most recent filing with the SEC.

COPYRIGHT VIOLATION NOTICE: “Alpine Immune Sciences (ALPN) Upgraded to Buy by Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/04/alpine-immune-sciences-alpn-upgraded-to-buy-by-zacks-investment-research.html.

Alpine Immune Sciences Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply